Claims for Patent: 4,772,475

Summary for Patent: 4,772,475

Title:	Controlled-release multiple units pharmaceutical formulation
Abstract:	A pharmaceutical controlled-release individual unit or multiple units formulation in which the individual unit comprises a granulation product obtained by adding a release controlling agent to a mixture of a physiologically active substance and units-forming substance(s) and granulating and resultant mixture, said granulation product (granules) being substantially not disintegrated but gradually releasing the physiologically active substance in the gastrointestinal tract.
Inventor(s):	Fukui; Muneo (Saitama, JP), Tomuro; Kouji (Saitama, JP), Masuyama; Shigeru (Saitama, JP), Kajiyama; Atsushi (Saitama, JP), Hikosaka; Tamio (Saitama, JP), Aruga; Masayoshi (Saitama, JP), Higuchi; Saburo (Saitama, JP), Soeishi; Yoshiaki (Tokyo, JP)
Assignee:	Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:	06/833,961
Patent Claims:	1. A pharmaceutical controlled-release individual unit or multiple unit formulation in which said individual unit consists essentially a granulation product obtained by adding a release controlling agent selected from the group consisting of acrylic acid polymers, acrylic acid copolymers and mixtures thereof with cellulose derivatives, to a mixture of physiologically active substances and crystalline cellulose, in an amount such that at least 50% by weight based on the weight of the units is said crystalline cellulose and granulating the resultant mixture and wherein said granulation product does not substantially disintegrate but gradually releases the physiologically active substance in the gastrointestinal tract. 2. The pharmaceutical formulation as claimed in claim 1, wherein the release controlling agent is a methacrylic acid-ethyl acrylate copolymer or mixtures of said copolymer and ethyl cellulose. 3. The pharmaceutical formulation as claimed in claim 1, wherein the release controlling agent further contains water. 4. The pharmaceutical formulation as claimed in claim 1, 2, or 3, wherein the physiologically active substance is 5-{2-[2-(o-ethoxypheoxy)ethylamino]propyl}-2-methoxybenzenesulfonamide hydrochloride (YM-12617). 5. The pharmaceutical formulation as claimed in claim 1, 2, 3, or 4, wherein the individual unit is granulation product having diameter of 0.1 to 1.5 mm.